London, January 10, 2026, 09:19 GMT — Market closed
- Smith & Nephew closed Friday roughly 0.9% lower, at 1,258p.
- CEO Deepak Nath is scheduled to speak at the J.P. Morgan Healthcare Conference on Jan. 12.
- The next major catalyst for the stock will be the company’s full-year results due March 2.
Smith & Nephew shares slipped on Friday as investors turn their attention to the company’s remarks at the J.P. Morgan Healthcare Conference this week.
The healthcare conference in San Francisco is already shaping up as a key barometer for sector mood and merger talk this year, with bankers and executives assembling in the city ahead of the event.
Smith & Nephew’s CEO Deepak Nath is set to speak on Monday, Jan. 12. The company’s investor calendar shows its next big update will be Q4 and full-year results, scheduled for March 2.
The FTSE 100 medical devices firm last changed hands at 1,258 pence, down from a previous close of 1,269 pence, after fluctuating between 1,255 and 1,272. The shares sit roughly 13% below their 52-week peak and about 34% above the year’s low, with traders watching to see if it can break back above 1,270p or fall below the 1,255p support level.
Investors are now focused less on the recent quarter and more on what 2026 holds. Back in December, the company unveiled its “RISE” strategy, laid out targets for 2028, and gave provisional guidance for 2026. Nath described the plan as “ambitious but achievable” in a company statement. smith-nephew.com
Some analysts are still cautious about the ambitious targets. “We remain nervous until the company can demonstrate reliably that it can generate this growth,” RBC Capital Markets analyst Jack Reynolds-Clark told Reuters on Dec. 8. Reuters
The risk is that JPM’s talk remains too high-level, while investors are looking for hard data — especially in orthopaedics, where U.S. knee sales have been a drag. Smith & Nephew’s stock took a hit in November after missing quarterly revenue forecasts, Reuters reported.
Macro factors might play a bigger role than usual for this steady medtech stock. The U.S. consumer price index for December is set to drop on Jan. 13. That report often shakes up bond yields and the dollar, which in turn can ripple through healthcare valuations and impact the translation of overseas earnings.
Next up for the stock is Monday’s conference call, where investors will be watching closely for tougher talk on 2026 execution and when orthopaedics might start to improve. After that, all eyes will shift to March 2, when Smith & Nephew releases its full-year results and is expected to reaffirm its 2026 guidance.
